Hansa Medical has received SEK 500,000 in financing from VINNOVA’s Forska&Väx (Research and Grow) program to implement a preliminary study in the framework of Hansa Medical’s TAME project. The objective of the project is to identify entirely new antibody-based methods for treating inflammatory diseases.“TAME, Therapeutic Antibodies Modified by EndoS, is an extremely exciting development project, but is still at an early phase. With this generous support from VINNOVA, we now have an opportunity to investigate how our patented EndoS enzyme can be used to create entirely new antibody-based therapy methods, primarily for the treatment of autoimmune diseases,” says Hansa Medical’s CEO, Emanuel Björne.In the first round of Forska&Väx in 2009, 69 small companies received financing with a total value of SEK 80 M. Some 308 proposals were received with a combined value of more than SEK 420 M.The Hansa Medical share is traded on First North under the ticker symbol HMED, and the company’s certified adviser is Remium AB.For more information, please contact:Emanuel Björne, CEOMobile: +46 707 17 54 77E-mail: emanuel.bjorne@hansamedical.com